AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21726411
Drug: Insulin Aspart/NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Aspart/NPH Insulin with Rosiglitazone/Placebo
Trial: 19562990
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) at a threshold of 0.5 ng/mL
Trial: 17206671
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 1 mg/g (1 g ointment twice a day)
Trial: 15502061
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) - 250 microg
Trial: 15502061
Drug: Ultrasound-assisted femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-assisted femoral nerve block (FNB) - 40 mL of 0.5% ropivacaine, 5 microg/mL of epinephrine, and 75 microg of clonidine
Trial: 9785066
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia combined with intercostal blockade (T7-T11) using 0.45% bupivacaine and 0.6% phenol
Trial: 9785066
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia alone
Trial: 8162986
Drug: ICI-204,219 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI-204,219 (20 mg)
Trial: 28646809
Drug: Fascial Distortion
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fascial Distortion Model (FDM) treatment
Trial: 28646809
Drug: NDMG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDMG treatment (control)
Trial: 23965206
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (15 mg/kg bolus before incision, followed by 15 mg/kg continuous infusion until skin closure)
Trial: 21075773
Drug: Implantable cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter defibrillator (ICD) only therapy
Trial: 8440429
Drug: Polidocanol 1%
RxNorm normalized name: POLIDOCANOL 1% INJ,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polidocanol 1% + adrenaline 1:10,000 injection
Trial: 3734514
Drug: Naftidrofuryl (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (200 mg t.i.d.)
Trial: 18657672
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/d for 3 days before surgery
Trial: 13678426
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (control group) attending hospital or practice based anticoagulant clinics.
Trial: 7697849
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n = 31)
Trial: 24277815
Drug: Sex hormone
RxNorm normalized name: Sex hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone binding globulin
Trial: 24277815
Drug: Endogenous sex
RxNorm normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endogenous sex steroid levels
Trial: 24277815
Drug: Hormone concentrations
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone concentrations
Trial: 19565542
Drug: T-614 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-614 50 mg/day for 24 weeks
Trial: 19565542
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 10 mg/week for 4 weeks and 15 mg/week for 20 weeks
Trial: 19565542
Drug: T-614 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-614 25 mg/day for 4 weeks and 50 mg/day for 20 weeks
Trial: 19565542
Drug: T-614 therapy
RxNorm normalized name: BCMA-CS1 cCAR T cell therapy
DrugBank: CAR BCMA-CS1 (DB17313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-614 therapy groups
Trial: 16397282
Drug: Otamixaban (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban (various intravenous doses)
Trial: 11109976
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraception (ethinylestradiol plus desogestrel) for 21 days each month for 12 months
Trial: 11109976
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraception (ethinylestradiol plus desogestrel) plus spironolactone daily for 12 months
Trial: 8371916
Drug: PhXA41 (0.006%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhXA41 (0.006% concentration, 60 micrograms/ml) administered once daily
Trial: 8371916
Drug: PhXA41 (0.006%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhXA41 (0.006% concentration, 60 micrograms/ml) administered twice daily
Trial: 8371916
Drug: PhXA41 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhXA41 (both dosing regimens)
Trial: 20392866
Drug: Metformin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin for 10 weeks
Trial: 15948994
Drug: Corticosteroid ointment
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid ointment regimen
Trial: 10561192
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) alone
Trial: 10561192
Drug: Sequential interleukin-3
RxNorm normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential interleukin-3 (IL-3) and GM-CSF
Trial: 1908478
Drug: hMG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG plus GnRH agonists (Group III)
Trial: 26869087
Drug: Iron +
RxNorm normalized name: Celebrate Iron + C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron + DHA/EPA combination
Trial: 22286978
Drug: Cefaclor formulation
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor formulation 1 (250 mg)
Trial: 22286978
Drug: Cefaclor formulation
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor formulation 2 (250 mg)
Trial: 20418301
Drug: Gabapentin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (15 mg/kg preoperatively, 5 mg/kg 3 times per day for 5 days postoperatively)
Trial: 17554473
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml paté
Trial: 17554473
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml egg white
Trial: 17554473
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml omelette
Trial: 17554473
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml radiolabeled omelette
Trial: 9834957
Drug: Slow‐dissolving formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow‐dissolving formulation
Trial: 9834957
Drug: Medium‐dissolving formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium‐dissolving formulation
Trial: 9834957
Drug: Fast‐dissolving formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast‐dissolving formulation
Trial: 9834957
Drug: Inderal 80
RxNorm normalized name: Inderal 80mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderal 80 mg
Trial: 2750531
Drug: 15 U/m2/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 U/m2/week of GH by daily subcutaneous injections for a mean of 0.82 years
Trial: 2750531
Drug: 30 U/m2/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 U/m2/week of GH by daily subcutaneous injections for a mean of 0.92 years
Trial: 789083
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (adjusted every two weeks to maintain serum level between 0.7 and 1.0 mmol/1)
Trial: 28846009
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg omega‐3 fatty acids plus 400 mg vitamin E
Trial: 26324672
Drug: ARB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB therapy (telmisartan)
Trial: 26324672
Drug: Non-ARB standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ARB standard therapy
Trial: 25168268
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg tabalumab Q4W
Trial: 25168268
Drug: 60/120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60/120 mg tabalumab Q4W
Trial: 25168268
Drug: 60/120/60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60/120/60 mg tabalumab Q4W
Trial: 22361261
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg three times daily for 6 weeks)
Trial: 12356283
Drug: Desmopressin (0.396
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.396 microg administered intravenously as a bolus injection)
Trial: 12356283
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (period preceding the 6th study day)
Trial: 10197827
Drug: Methylphenidate therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate therapy
Trial: 7191299
Drug: Bay g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay g 5421 (acarbose)
Trial: 23572075
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg/d, twice daily for 28 days)
Trial: 23572075
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 28 days)
Trial: 21980828
Drug: Suplatast tosilate
RxNorm normalized name: Edoxaban Tosylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suplatast tosilate (100 mg orally 3 times a day for 2 years)
Trial: 21980828
Drug: Fluticasone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (100 pg inhaled twice a day for 2 years)
Trial: 27893087
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care plus 2 years of home‐based occupational therapy
Trial: 22823871
Drug: α(1)-blockade (prazosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α(1)-blockade (prazosin, 1 mg/20 kg body weight)
Trial: 20595648
Drug: Milled flaxseed
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milled flaxseed (FXS, n = 13; 32 g/d)
Trial: 20595648
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (FXO, n = 12; 13 g/d)
Trial: 17592102
Drug: Rosiglitazone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (2 mg/d)
Trial: 12149202
Drug: ADE (cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADE (cytarabine 100 mg/m(2)/d by 7‐day infusion, daunorubicin 60 mg/m(2) and etoposide 100 mg/m(2) daily for 3 days)
Trial: 12149202
Drug: ADEP (daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADEP (daunorubicin 40 mg/m(2) and etoposide 60 mg/m(2) for 3 days with PSC‐833, 2.8 mg/kg over 2 hours, and then 10 mg/kg/d by 3‐day infusion)
Trial: 10084159
Drug: Tegretol CR
RxNorm normalized name: Tegretol
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tegretol CR 200 (commercially available controlled-release carbamazepine preparation)
Trial: 2111251
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac potassium three times daily for 7 days
Trial: 2111251
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day piroxicam for 7 days
Trial: 6963332
Drug: Aspirin (ASA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA), 600 mg, p.o., twice daily for 2 years
Trial: 30688523
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with 5‐fluorouracil and oxaliplatin (FOLFOX)
Trial: 25938131
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium nitrite 0.5% cream
Trial: 25938131
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium nitrite 1.0% cream
Trial: 25938131
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium nitrite 1.5% cream
Trial: 25938131
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium nitrite 1.8% cream
Trial: 25938131
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium nitrite 2.0% cream
Trial: 21967073
Drug: Individual virtual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual virtual reality exposure therapy
Trial: 17502577
Drug: Otamixaban (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban (highest dose)
Trial: 17502577
Drug: Otamixaban (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban (doses 1 to 5)
Trial: 17290435
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to approximately 1600 mT (twice)
Trial: 14981398
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with protease inhibitor (PI) early
Trial: 14981398
Drug: Combination without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination without protease inhibitor (PI)
Trial: 14981398
Drug: Monotherapy (monoRx)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (monoRx) early
Trial: 14981398
Drug: Monotherapy (monoRx)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (monoRx) late
Trial: 14981398
Drug: Combination without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination without protease inhibitor (PI) late
Trial: 14981398
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with protease inhibitor (PI) late
Trial: 8769693
Drug: No IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IFN (standard chemotherapy: busulphan or hydroxyurea)
Trial: 1732125
Drug: Naloxone infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusions (0.2 micrograms.kg‐1.min‐1)
Trial: 11668421
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin certoparin (8000 antifactor Xa U b.i.d.)
Trial: 11668421
Drug: Adjusted-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose intravenous unfractionated heparin (UFH)
Trial: 9835755
Drug: 150 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms of oral clonidine
Trial: 31511563
Drug: Psychoactive compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoactive compounds (CANDO platform predictions)
Trial: 29061968
Drug: Olodaterol 5 µg
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 5 µg QD via Respimat®
Trial: 29061968
Drug: Formoterol 12 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 µg BID
Trial: 24386960
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injection (50 U injected intracutaneously into 6-20 sites)
Trial: 14723752
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg by mouth followed in two days by vaginal then oral misoprostol (Aberdeen regimen)
Trial: 10355844
Drug: Pyruvate supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyruvate supplementation (6 g/d)
Trial: 7721404
Drug: Irbesartan 10
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan 10 mg
Trial: 2201664
Drug: Oral L-Dopa
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral L-Dopa
Trial: 7030443
Drug: Chlorpromazine plus
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine plus high dose propranolol
Trial: 19112224
Drug: Iodixanol (Visipaque)
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol (Visipaque) 50 mL
Trial: 19112224
Drug: Iohexol (Omnipaque)
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iohexol (Omnipaque) 50 mL
Trial: 8285510
Drug: Multichannel cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multichannel cochlear implants
Trial: 19034471
Drug: 50 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mug misoprostol intravaginally every 4 h to a maximum of five doses
Trial: 19034471
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dinoprostone vaginal insert for a maximum of 12 h
Trial: 17523399
Drug: Allicor (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allicor (a long‐action garlic‐based preparation) administered for 12 months